Physician

Stephan D Kendall, M.D.

According to 2025 Medicare claims, Stephan Kendall, M.D. (NPI: 1033293196) practices medical oncology in the Salt Lake City-Murray, UT market, with the plurality of this provider's patient population coming from Salt Lake, UT. This provider's primary affiliated billing organization is UTAH CANCER SPECIALISTS PC (NPI: 1619925369; TIN: 870519691) and primary practice location at 84106-1494. Kendall is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Kendall's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 315 traditional Medicare patients, billed 79,085 HCPCS/CPT codes, and received $994,610 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 769 prescription claims across 147 beneficiaries totaling $3,545,804 in drug costs, led by Brukinsa (Zanubrutinib). 2020 DME data shows 58 claims. Open Payments data shows 227 records totaling $1,287,628. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,186,311 and ending at $994,610. Concurrently, Part D prescription costs have risen steadily, from $1,206,304 to $3,545,804. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $839 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	344	79,906	$1,186,311
2016	337	47,815	$575,072
2017	450	85,391	$1,208,459
2018	459	86,391	$1,484,899
2019	456	86,301	$1,409,390
2020	421	67,336	$1,173,949
2021	417	94,864	$1,847,485
2022	410	79,610	$1,323,442
2023	291	67,211	$739,869
2024	315	79,085	$994,610

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	780	$1,206,304
2016	145	752	$1,543,276
2017	149	779	$2,109,075
2018	145	803	$1,826,600
2019	117	732	$1,602,134
2020	120	665	$1,356,573
2021	123	741	$2,000,069
2022	122	700	$2,577,217
2023	136	694	$2,126,003
2024	147	769	$3,545,804

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	32	$40,631
2016	N/R	31	$16,539
2017	N/R	36	$15,705
2018	N/R	53	$9,038
2019	N/R	N/R	N/R
2020	N/R	58	$5,768
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	123	272	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	137	215	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	55	67	$12
80053	Blood test, comprehensive group of blood chemicals	203	474	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	246	609	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	52	1,531	$727,076
Ibrance	Palbociclib	30	840	$462,609
Lenvima	Lenvatinib Mesylate	17	510	$459,876
Xtandi	Enzalutamide	21	630	$265,585
Bosulif	Bosutinib	13	390	$230,715

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$965	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	163	$1,286,663	Aadi Bioscience, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$7,071	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Stephan D. Kendall, M.D.?

Tedicare shows public-source Medicare data for Stephan D. Kendall, M.D. (NPI 1033293196), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephan D. Kendall, M.D. have ACO affiliation data?

Stephan D. Kendall, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Stephan D. Kendall, M.D.?

Stephan D. Kendall, M.D. is linked to UTAH CANCER SPECIALISTS PC (billing NPI 1619925369) in the available physician profile data.

Does Stephan D. Kendall, M.D. have Open Payments data?

Stephan D. Kendall, M.D. has 227 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.